Chasing Biogen, the Pliant crew banks a $62M round to fuel their shot at fibrosis targets

South San Francisco-based Pliant Therapeutics has just closed a $62 million round to take their idiopathic pulmonary fibrosis drug to the clinic — the first of many fibrotic disease-targeting drugs it hopes will come out of its discovery engine.